RecoveryResearch Phase

Pentadeca Arginate (PDA)

Subcutaneous injection, Topical

Overview

Pentadeca Arginate is a synthetic 15-arginine polypeptide designed to enhance cellular uptake and delivery of therapeutic molecules. The polyarginine structure confers cell-penetrating properties by interacting with negatively charged cell membrane components.

Mechanism of Action

It has been explored as a carrier for facilitating intracellular delivery of bioactive compounds and as a potential modulator of tissue repair processes..

Research Summary & Key Findings

Preclinical in vitro studies have demonstrated efficient cellular internalization and low cytotoxicity in various cell lines. Animal studies investigating wound healing and tissue repair applications have shown preliminary evidence of enhanced regeneration, though mechanisms remain incompletely characterized. No clinical trial data in humans are currently available.

Clinical Status

Research Phase

Pentadeca Arginate (PDA) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionTopical

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers Pentadeca Arginate (PDA) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Pentadeca Arginate (PDA).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.